Cabotegravir is an integrase strand transfer inhibitor analog of Tivicay (dolutegravir; ViiV Healthcare), and rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), branded as Edurant (Johnson & Johnson).
Cabotegravir/rilpivirine is anticipated to be the first long-acting injectable (LAI) to enter the HIV market, and has demonstrated non-inferiority to standard-of-care three-drug regimens in virologically suppressed patients. Datamonitor Healthcare expects uptake to be primarily driven by patients who would favor the LAI over a once-daily oral drug. Indeed, key opinion leaders have reported that a minority of patients are eager to receive dosing once every four weeks and possibly once every eight weeks in order to avoid a daily reminder of their HIV infection and the associated stigma. However, while ViiV Healthcare and Johnson & Johnson are expected to tout the LAI as an attractive option for patients with poor adherence to their existing once-daily treatment regimen, key opinion leaders have voiced concerns over this approach due to the increased potential for resistance generation if patients are also poorly adherent to the LAI.
4 Drug Overview
5 Product Profiles
5 cabotegravir/rilpivirine : HIV
LIST OF FIGURES
10 Figure 56: Datamonitor Healthcare’s drug assessment summary of fostemsavir for HIV
11 Figure 57: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2018–27
13 Figure 58: Datamonitor Healthcare’s drug assessment summary of leronlimab for HIV
LIST OF TABLES
6 Table 1: Cabotegravir/rilpivirine drug profile
8 Table 2: Late-phase trials of cabotegravir/rilpivirine for HIV
9 Table 3: Cabotegravir/rilpivirine for HIV – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.